Xilio Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 66.3% | 66.3% | -152.0% |
| FY2021 | -40.9% | -40.9% | -34.8% |
| FY2022 | -83.5% | -83.5% | -63.4% |
| FY2023 | -207.5% | -207.5% | -125.4% |
| FY2024 | -331.0% | -331.0% | -81.9% |
| FY2025 | -99.3% | -99.3% | -22.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 66.3% | 66.3% | -152.0% |
| FY2021 | -40.9% | -40.9% | -34.8% |
| FY2022 | -83.5% | -83.5% | -63.4% |
| FY2023 | -207.5% | -207.5% | -125.4% |
| FY2024 | -331.0% | -331.0% | -81.9% |
| FY2025 | -99.3% | -99.3% | -22.6% |